The treatment of HCV infection has evolved at an extremely rapid pace over the past few
years. The development of direct-acting antiviral agents, which potently inhibit different …

Hepatitis C virus (HCV) infection is a global health problem that impacts approximately 180
million individuals. Of those initially infected with HCV approximately 80% will progress to …

The rapidly expanding Zika virus (ZIKV) epidemic has affected thousands of individuals with
severe cases causing Guillain-Barré syndrome, congenital malformations, and …

Nucleotide analog inhibitors have shown clinical success in the treatment of hepatitis C virus
(HCV) infection, despite an incomplete mechanistic understanding of NS5B, the viral RNA …

Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects
Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials | Clinical Infectious Diseases …

ABSTRACT PSI-7977, a prodrug of 2′-F-2′-C-methyluridine monophosphate, is the
purified diastereoisomer of PSI-7851 and is currently being investigated in phase 3 clinical …

Abstract SARS‐CoV‐2, a member of the coronavirus family, has caused a global public
health emergency. Based on our analysis of hepatitis C virus and coronavirus replication …

The RNA-dependent RNA polymerases (RdRPs) encoded by the RNA viruses are a unique
class of nucleic acid polymerases. Each viral RdRP contains a 500–600 residue catalytic …

The C-terminal region of Clostridium perfringens enterotoxin (C-CPE) can bind to specific
claudins, resulting in the disintegration of tight junctions (TJs) and an increase in the …

Nucleoside/tide analogues (NAs) have long been used in the fight against viral diseases,
and now present a promising option for the treatment of COVID-19. Once activated to the 5 …